Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.96) by 13.72 percent. This is a 34.65 percent increase over losses of $(1.27) per share from the same period last year. The company reported quarterly sales of $23.017 million which beat the analyst consensus estimate of $12.812 million by 79.65 percent. This is a 78.79 percent increase over sales of $12.874 million the same period last year.